ATE363533T1 - Osteoprotegerin bindende proteine und rezeptoren - Google Patents

Osteoprotegerin bindende proteine und rezeptoren

Info

Publication number: ATE363533T1
Authority: AT; Austria
Prior art keywords: fragments; encoding; sequence; nucleic acid; receptors
Prior art date: 1997-04-16

Application number

AT98918244T

Other languages

English (en)

Inventor

William Boyle

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-16

Filing date

1998-04-15

Publication date

2007-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27368158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE363533(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-04-16 Priority claimed from US08/842,842 external-priority patent/US5843678A/en

1998-03-30 Priority claimed from US09/052,521 external-priority patent/US6316408B1/en

1998-04-15 Application filed by Amgen Inc filed Critical Amgen Inc

2007-06-15 Application granted granted Critical

2007-06-15 Publication of ATE363533T1 publication Critical patent/ATE363533T1/de

Links

102000014914 Carrier Proteins Human genes 0.000 title abstract 2
108091008324 binding proteins Proteins 0.000 title abstract 2
102000008108 Osteoprotegerin Human genes 0.000 title 1
108010035042 Osteoprotegerin Proteins 0.000 title 1
XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 title 1
102000005962 receptors Human genes 0.000 title 1
108020003175 receptors Proteins 0.000 title 1
239000012634 fragment Substances 0.000 abstract 3
150000007523 nucleic acids Chemical class 0.000 abstract 3
102000039446 nucleic acids Human genes 0.000 abstract 2
108020004707 nucleic acids Proteins 0.000 abstract 2
208000020084 Bone disease Diseases 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
230000004069 differentiation Effects 0.000 abstract 1
239000013604 expression vector Substances 0.000 abstract 1
210000002997 osteoclast Anatomy 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Immunology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Orthopedic Medicine & Surgery (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Steroid Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT98918244T 1997-04-16 1998-04-15 Osteoprotegerin bindende proteine und rezeptoren ATE363533T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/842,842 US5843678A (en)	1997-04-16	1997-04-16	Osteoprotegerin binding proteins
US88085597A	1997-06-23	1997-06-23
US09/052,521 US6316408B1 (en)	1997-04-16	1998-03-30	Methods of use for osetoprotegerin binding protein receptors

Publications (1)

Publication Number	Publication Date
ATE363533T1 true ATE363533T1 (de)	2007-06-15

Family

ID=27368158

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98918244T ATE363533T1 (de)	1997-04-16	1998-04-15	Osteoprotegerin bindende proteine und rezeptoren

Country Status (27)

Country	Link
US (1)	US7923008B2 (de)
EP (2)	EP1717315A3 (de)
JP (2)	JP2001526532A (de)
CN (1)	CN1264427A (de)
AT (1)	ATE363533T1 (de)
AU (4)	AU743257B2 (de)
BG (1)	BG65242B1 (de)
BR (1)	BR9808545A (de)
CA (1)	CA2285746C (de)
CZ (1)	CZ302262B6 (de)
DE (1)	DE69837845T3 (de)
DK (1)	DK0975754T4 (de)
EA (1)	EA003636B1 (de)
EE (1)	EE05496B1 (de)
ES (1)	ES2284203T5 (de)
HU (1)	HU230547B1 (de)
ID (1)	ID23855A (de)
IL (1)	IL132304A0 (de)
NO (1)	NO325175B1 (de)
NZ (1)	NZ500253A (de)
PL (1)	PL190092B1 (de)
RO (1)	RO128635A2 (de)
SI (1)	SI0975754T2 (de)
SK (1)	SK288559B6 (de)
TR (1)	TR199902512T2 (de)
TW (1)	TW589376B (de)
WO (1)	WO1998046751A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL117175A (en)	1995-02-20	2005-11-20	Sankyo Co	Osteoclastogenesis inhibitory factor protein
PT1114864E (pt) *	1996-12-13	2008-10-08	Schering Corp	Antigénios de superfície de células de mamífero, reagentes relacionados
PT951551E (pt)	1996-12-23	2008-10-28	Immunex Corp	Ligando para receptor activador de nf-kb, ligando membro da superfamília de tnf
US6271349B1 (en)	1996-12-23	2001-08-07	Immunex Corporation	Receptor activator of NF-κB
WO1998046644A1 (fr)	1997-04-15	1998-10-22	Snow Brand Milk Products Co., Ltd.	Nouvelle proteine et methode de production associee
AU2008200700C1 (en) *	1997-04-15	2013-04-04	Daiichi Sankyo Co., Ltd	Novel Protein and Process for Producing The Same
SI0975754T2 (sl)	1997-04-16	2016-04-29	Amgen Inc.,	Vezivni proteini in receptorji osteoprotegerina
US6316408B1 (en)	1997-04-16	2001-11-13	Amgen Inc.	Methods of use for osetoprotegerin binding protein receptors
EP1076699B1 (de)	1998-05-14	2008-10-29	Immunex Corporation	Verfahren zur hemmung der wirkung der osteoklasten
US20020106728A1 (en) *	2000-06-20	2002-08-08	Genentech, Inc.	NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
EP1541587A3 (de) *	1998-09-15	2007-06-20	Pharmexa A/S	Verfahren zur Hemmung der Wirkung von Osteoprotegerin-Ligand
HK1040261A1 (zh) *	1998-09-15	2002-05-31	法麦克萨有限公司	负调节osteoprotegerin配体活性的方法
HK1042114B (zh)	1998-10-23	2006-09-29	Amgen K-A, Inc.	与mp1受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽
JP5118796B2 (ja)	1999-06-28	2013-01-16	ジェネンテック，インコーポレイテッド	二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法
PL211786B1 (pl)	1999-08-17	2012-06-29	Apoxis Sa	Zastosowanie przeciwciała oraz polipeptydu
WO2001023559A1 (en) *	1999-09-27	2001-04-05	Eli Lilly And Company	Osteoclast differentiation factor regulatory region
AUPQ314799A0 (en) *	1999-09-29	1999-10-21	University Of Western Australia, The	Bone cell factor
AU2048501A (en)	2000-02-16	2001-08-27	Genentech Inc.	Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20030103978A1 (en) *	2000-02-23	2003-06-05	Amgen Inc.	Selective binding agents of osteoprotegerin binding protein
SI1257648T2 (sl) †	2000-02-23	2016-11-30	Amgen Inc.	Antagonistični selektivni vezavni agensi za osteoprotegerin vezavni protein
US6600018B1 (en)	2000-04-10	2003-07-29	The United States Of America As Represented By The Department Of Health And Human Services	Secreted frizzled related protein, sFRP, fragments and methods of use thereof
AU2001247616B2 (en)	2000-04-11	2007-06-14	Genentech, Inc.	Multivalent antibodies and uses therefor
ATE415978T1 (de)	2000-07-27	2008-12-15	Genentech Inc	Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
US20040247596A1 (en) *	2000-08-18	2004-12-09	Odgren Paul R.	TRANCE regulation of chondrocyte differentiation
CA2423052C (en)	2000-09-22	2011-07-12	Immunex Corporation	Screening assays for agonists or antagonists of receptor activator of nf-kb
WO2002055547A2 (en)	2001-01-10	2002-07-18	The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services	Sfrp and peptide motifs that interact with sfrp and methods of their use
US7128911B2 (en)	2001-01-19	2006-10-31	Cytos Biotechnology Ag	Antigen arrays for treatment of bone disease
CA2451955C (en) *	2001-06-26	2015-09-29	Abgenix, Inc.	Antibodies to opgl
PT1409544E (pt)	2001-07-03	2009-09-16	Genentech Inc	Anticorpos de dr4 humanos e suas utilizações
WO2003029420A2 (en)	2001-10-02	2003-04-10	Genentech, Inc.	Apo-2 ligand variants and uses thereof
EP1450847B1 (de)	2001-11-13	2010-09-29	Genentech, Inc.	Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung
US7842668B1 (en)	2001-11-13	2010-11-30	Genentech, Inc.	Apo-2 ligand/trail formulations
US7741285B2 (en)	2001-11-13	2010-06-22	Genentech, Inc.	APO-2 ligand/trail formulations
EP2314316A1 (de) *	2002-04-05	2011-04-27	Amgen, Inc	Humane neutralizierende anti-OPGL Antikörper als selektive OPGL Pathway Inhibitoren
AU2011265413B2 (en) *	2002-04-05	2014-04-10	Amgen Inc.	Human Anti-OPGL Neutralizing Antibodies as Selective OPGL, Pathway Inhibitors
EP2500032A1 (de)	2002-06-24	2012-09-19	Genentech, Inc.	APO-2-Liganden-/Trailvarianten und Verwendungen dafür
JP2006521084A (ja)	2002-12-10	2006-09-21	シェーリング−プラウ・リミテッド	イヌｒａｎｋｌならびにイヌｒａｎｋｌを調製および使用するための方法
CA2572765C (en)	2004-07-08	2013-05-21	Amgen Inc.	Compound having improved bioefficiency when administered in a multidose regimen
RU2410438C2 (ru)	2004-08-06	2011-01-27	Дженентек, Инк.	Анализы и способы, использующие биомаркеры
DE602005027848D1 (de)	2004-08-06	2011-06-16	Genentech Inc	Tests und verfahren unter verwendung von biomarkern
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
US8029783B2 (en)	2005-02-02	2011-10-04	Genentech, Inc.	DR5 antibodies and articles of manufacture containing same
AU2006279618A1 (en)	2005-08-16	2007-02-22	Genentech, Inc.	Apoptosis sensitivity to Apo2L/TRAIL by testing for 'GalNac-T14 expression in cells/tissues
AR056806A1 (es)	2005-11-14	2007-10-24	Amgen Inc	Moleculas quimericas de anticuerpo rankl- pth/ pthrp
US9726673B2 (en)	2005-11-23	2017-08-08	Genentech, Inc.	Methods and compositions related to B cell assays
US20090227032A1 (en)	2005-12-13	2009-09-10	Kyoto University	Nuclear reprogramming factor and induced pluripotent stem cells
US9283260B2 (en)	2006-04-21	2016-03-15	Amgen Inc.	Lyophilized therapeutic peptibody formulations
US8378084B2 (en) *	2006-12-22	2013-02-19	The Regents Of The University Of California	Fusion molecule based on novel TAA variant
EP2738257A1 (de)	2007-05-22	2014-06-04	Amgen Inc.	Zusammensetzungen und Verfahren zur Herstellung bioaktiver Fusionsproteine
JP2008307007A (ja)	2007-06-15	2008-12-25	Bayer Schering Pharma Ag	出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
HRP20140405T1 (hr) *	2007-06-20	2014-06-20	Galapagos N.V.	Molekularni ciljevi i metode za identificiranje spojeva za lijeäśenje degenerativnih bolesti kostiju i zglobova
CN101855350B (zh) *	2008-05-02	2014-12-31	国立大学法人京都大学	核重编程序方法
MX2011005481A (es)	2008-11-25	2011-08-17	Biogen Idec Inc	Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso.
EP2434285A1 (de)	2010-09-22	2012-03-28	IMBA-Institut für Molekulare Biotechnologie GmbH	Brustkrebsdiagnose
EP2433644A1 (de)	2010-09-22	2012-03-28	IMBA-Institut für Molekulare Biotechnologie GmbH	Brustkrebstherapeutika
JP2015514686A (ja)	2012-02-29	2015-05-21	コヨーテ・ファーマシューティカルズ・インコーポレイテッドＣｏｙｏｔｅＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｇｇａ及びそのｇｇａ誘導体組成物並びにこれらを含む麻痺状態を含めた神経変性疾患を治療する方法
US9119808B1 (en)	2012-10-08	2015-09-01	Coyote Pharmaceuticals, Inc.	Treating neurodegenerative diseases with GGA or a derivative thereof
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
WO2014144817A2 (en)	2013-03-15	2014-09-18	Amgen Inc.	Inhibitory polypeptides specific to wnt inhibitors
CA2923145C (en)	2013-09-05	2025-09-16	Amgen Inc.	MOLECULES CONTAINING FCS AND EXHIBITING PREDICTABLE, UNIFORM AND REPRODUCIBLE GLYCOFORM PROFILES
MX377275B (es)	2014-05-16	2025-03-07	Amgen Inc	Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
WO2018138297A1 (en)	2017-01-27	2018-08-02	Kymab Limited	Anti-opg antibodies
AU2018235928B2 (en)	2017-03-14	2023-09-21	Amgen Inc.	Control of total afucosylated glycoforms of antibodies produced in cell culture
US11654153B2 (en)	2017-11-22	2023-05-23	Inbiomotion S.L.	Therapeutic treatment of breast cancer based on c-MAF status
CN119639849A (zh)	2018-03-26	2025-03-18	美国安进公司	细胞培养物中产生的抗体的总去岩藻糖基化糖型
AU2020355251A1 (en)	2019-09-26	2022-04-21	Amgen Inc.	Methods of producing antibody compositions
CN113621060B (zh) *	2020-05-07	2023-07-04	浙江瑞硕生物技术有限公司	一种opg抗体对及其应用
WO2021247892A1 (en)	2020-06-04	2021-12-09	Amgen Inc.	Assessment of cleaning procedures of a biotherapeutic manufacturing process
AU2021360897A1 (en)	2020-10-15	2023-05-25	Amgen Inc.	Relative unpaired glycans in antibody production methods
AR126089A1 (es)	2021-06-07	2023-09-13	Amgen Inc	Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
WO2023059607A1 (en)	2021-10-05	2023-04-13	Amgen Inc.	Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en)	2022-05-02	2023-11-09	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
AU2024256160A1 (en)	2023-04-20	2025-10-02	Amgen Inc.	Methods of determining relative unpaired glycan content
AU2024325342A1 (en)	2023-08-14	2026-02-26	Amgen Inc.	Methods for reducing yellow color
WO2025101820A1 (en)	2023-11-08	2025-05-15	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
WO2026090253A1 (en)	2024-10-23	2026-04-30	Amgen Inc.	Methods of determining glycan pairing content

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4710457A (en)	1983-06-29	1987-12-01	Sloan-Kettering Institute For Cancer Research	Monoclonal antibody for human hematopoietic glycoproteins and method
US4710473A (en)	1983-08-10	1987-12-01	Amgen, Inc.	DNA plasmids
US4959314A (en)	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
US6410516B1 (en)	1986-01-09	2002-06-25	President & Fellows Of Harvard College	Nuclear factors associated with transcriptional regulation
US5846534A (en)	1988-02-12	1998-12-08	British Technology Group Limited	Antibodies to the antigen campath-1
EP0513334A4 (en)	1990-11-30	1993-08-04	Celtrix Laboratories, Inc.	Use of a bone morphogenetic protein in synergistic combination with tgf--g(b) for bone repair
US5118667A (en)	1991-05-03	1992-06-02	Celtrix Pharmaceuticals, Inc.	Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en)	1991-05-13	1992-11-14	Masahiko Sato	Method for inhibiting bone resorption
MX9204303A (es)	1991-07-23	1993-11-01	Rhone Poulenc Rorer Int	Factor regulador del crecimiento de osteoclasto.
IL99120A0 (en)	1991-08-07	1992-07-15	Yeda Res & Dev	Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5961974A (en)	1991-10-25	1999-10-05	Immunex Corporation	Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5447851B1 (en)	1992-04-02	1999-07-06	Univ Texas System Board Of	Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
EP0639079B1 (de)	1992-04-30	2000-01-12	Amgen Inc.	Methoden zur Behandlung von Interleukin- 1 und - Tumor - Nekrose - Faktor - verursachten Krankheiten
US5585479A (en)	1992-07-24	1996-12-17	The United States Of America As Represented By The Secretary Of The Navy	Antisense oligonucleotides directed against human ELAM-I RNA
US5578569A (en)	1993-03-12	1996-11-26	Tam; Cherk S.	Method of increasing bone growth
US5457035A (en)	1993-07-23	1995-10-10	Immunex Corporation	Cytokine which is a ligand for OX40
WO1995007935A1 (en)	1993-09-14	1995-03-23	Merck & Co., Inc.	cDNA ENCODING A NOVEL HUMAN PROTEIN TYROSINE PHOSPHATASE
US6268212B1 (en)	1993-10-18	2001-07-31	Amgen Inc.	Tissue specific transgene expression
US5641747A (en)	1994-07-25	1997-06-24	Temple University-Of The Commonwealth System Of Higher Education	Treatment of osteopetrotic diseases
WO1996014328A1 (en) *	1994-11-07	1996-05-17	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
AU4440496A (en)	1995-02-10	1996-08-22	Smithkline Beecham Corporation	Use of src SH2 specific compounds to treat a bone resorption disease
IL117175A (en)	1995-02-20	2005-11-20	Sankyo Co	Osteoclastogenesis inhibitory factor protein
US20030166097A1 (en)	1995-03-15	2003-09-04	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor
US7094564B1 (en)	1995-03-15	2006-08-22	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor
WO1996028546A1 (en)	1995-03-15	1996-09-19	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor
AU5985996A (en)	1995-06-07	1997-01-15	Osteosa Inc.	Osteoclast growth regulatory factor
WO1997000318A1 (en)	1995-06-07	1997-01-03	Osteosa Inc.	Osteoclast growth regulatory factor
US5843901A (en)	1995-06-07	1998-12-01	Advanced Research & Technology Institute	LHRH antagonist peptides
KR100510234B1 (ko)	1995-06-29	2005-11-25	임뮤넥스 코포레이션	세포소멸을 유도하는 시토킨
US6613544B1 (en)	1995-12-22	2003-09-02	Amgen Inc.	Osteoprotegerin
US6369027B1 (en)	1995-12-22	2002-04-09	Amgen Inc.	Osteoprotegerin
US6046048A (en)	1996-01-09	2000-04-04	Genetech, Inc.	Apo-2 ligand
US5981220A (en)	1996-03-27	1999-11-09	Human Genome Sciences, Inc.	Epidermal differentiation factor
TW555765B (en) *	1996-07-09	2003-10-01	Amgen Inc	Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JPH1057071A (ja)	1996-08-19	1998-03-03	Snow Brand Milk Prod Co Ltd	新規ｄｎａ及びそれを用いた蛋白質の製造方法
PT1114864E (pt)	1996-12-13	2008-10-08	Schering Corp	Antigénios de superfície de células de mamífero, reagentes relacionados
EP0951546A2 (de)	1996-12-20	1999-10-27	The Board Of Regents, The University Of Texas System	Zusammensetzungen und verfahren zur verwendung von osteoklasthemmenden faktoren
FR2757507B1 (fr)	1996-12-20	1999-01-29	Inst Francais Du Petrole	Procede de separation de paraxylene comprenant une adsorption avec injection d'eau et une cristallisation
US6271349B1 (en)	1996-12-23	2001-08-07	Immunex Corporation	Receptor activator of NF-κB
PT951551E (pt) *	1996-12-23	2008-10-28	Immunex Corp	Ligando para receptor activador de nf-kb, ligando membro da superfamília de tnf
WO1998046644A1 (fr)	1997-04-15	1998-10-22	Snow Brand Milk Products Co., Ltd.	Nouvelle proteine et methode de production associee
SI0975754T2 (sl)	1997-04-16	2016-04-29	Amgen Inc.,	Vezivni proteini in receptorji osteoprotegerina
US5843678A (en)	1997-04-16	1998-12-01	Amgen Inc.	Osteoprotegerin binding proteins
US6316408B1 (en)	1997-04-16	2001-11-13	Amgen Inc.	Methods of use for osetoprotegerin binding protein receptors
CA2229449A1 (en) *	1997-04-25	1998-10-25	Takeda Chemical Industries, Ltd.	Novel receptor protein and its use
AU7469998A (en)	1997-05-01	1998-11-24	Amgen, Inc.	Chimeric opg polypeptides
WO1998054201A1 (en)	1997-05-29	1998-12-03	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor-like protein 8
US6087555A (en)	1997-10-15	2000-07-11	Amgen Inc.	Mice lacking expression of osteoprotegerin
US6790823B1 (en)	1998-04-23	2004-09-14	Amgen Inc.	Compositions and methods for the prevention and treatment of cardiovascular diseases
EP1076699B1 (de)	1998-05-14	2008-10-29	Immunex Corporation	Verfahren zur hemmung der wirkung der osteoklasten
HK1040261A1 (zh)	1998-09-15	2002-05-31	法麦克萨有限公司	负调节osteoprotegerin配体活性的方法
AU6078500A (en)	1999-07-09	2001-01-30	Amgen, Inc.	Combination therapy for conditions leading to bone loss
WO2001017543A2 (en)	1999-09-03	2001-03-15	Amgen Inc.	Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
US20030144187A1 (en)	1999-09-03	2003-07-31	Colin R. Dunstan	Opg fusion protein compositions and methods
SI1257648T2 (sl)	2000-02-23	2016-11-30	Amgen Inc.	Antagonistični selektivni vezavni agensi za osteoprotegerin vezavni protein
US20030103978A1 (en)	2000-02-23	2003-06-05	Amgen Inc.	Selective binding agents of osteoprotegerin binding protein
US20040247596A1 (en)	2000-08-18	2004-12-09	Odgren Paul R.	TRANCE regulation of chondrocyte differentiation
CA2423052C (en)	2000-09-22	2011-07-12	Immunex Corporation	Screening assays for agonists or antagonists of receptor activator of nf-kb
CA2447518A1 (en)	2001-05-17	2002-11-21	Immunex Corporation	Therapeutic use of rank antagonists
EP1432438A2 (de)	2001-06-06	2004-06-30	Immunex Corporation	Verwendung von rang-antagonisten zur behandlung von krebs
CA2451955C (en)	2001-06-26	2015-09-29	Abgenix, Inc.	Antibodies to opgl
US6753755B2 (en) *	2001-06-28	2004-06-22	Safer Home, Inc.	Electrical safety connector fuse
US7084257B2 (en) *	2001-10-05	2006-08-01	Amgen Inc.	Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US6592001B2 (en) *	2001-12-18	2003-07-15	Kimberly-Clark Worldwide	Dispenser for sheet material containing a dispensing port incrementally variable within a range
EP2314316A1 (de)	2002-04-05	2011-04-27	Amgen, Inc	Humane neutralizierende anti-OPGL Antikörper als selektive OPGL Pathway Inhibitoren
US7706431B2 (en) *	2005-06-30	2010-04-27	Nokia Corporation	System and method for providing optimized receiver architectures for combined pilot and data signal tracking

1998
- 1998-04-15 SI SI9830889T patent/SI0975754T2/sl unknown
- 1998-04-15 RO ROA201200577A patent/RO128635A2/ro unknown
- 1998-04-15 PL PL98336311A patent/PL190092B1/pl unknown
- 1998-04-15 ES ES98918244.9T patent/ES2284203T5/es not_active Expired - Lifetime
- 1998-04-15 CN CN98806073A patent/CN1264427A/zh active Pending
- 1998-04-15 DE DE69837845.8T patent/DE69837845T3/de not_active Expired - Lifetime
- 1998-04-15 TR TR1999/02512T patent/TR199902512T2/xx unknown
- 1998-04-15 WO PCT/US1998/007584 patent/WO1998046751A1/en not_active Ceased
- 1998-04-15 EP EP06015956A patent/EP1717315A3/de not_active Withdrawn
- 1998-04-15 EP EP98918244.9A patent/EP0975754B2/de not_active Expired - Lifetime
- 1998-04-15 ID IDW991225A patent/ID23855A/id unknown
- 1998-04-15 DK DK98918244.9T patent/DK0975754T4/en active
- 1998-04-15 CA CA2285746A patent/CA2285746C/en not_active Expired - Lifetime
- 1998-04-15 AU AU71205/98A patent/AU743257B2/en not_active Ceased
- 1998-04-15 JP JP54425798A patent/JP2001526532A/ja not_active Withdrawn
- 1998-04-15 BR BR9808545-0A patent/BR9808545A/pt not_active Application Discontinuation
- 1998-04-15 EA EA199900939A patent/EA003636B1/ru not_active IP Right Cessation
- 1998-04-15 IL IL13230498A patent/IL132304A0/xx unknown
- 1998-04-15 CZ CZ0359899A patent/CZ302262B6/cs not_active IP Right Cessation
- 1998-04-15 EE EEP199900611A patent/EE05496B1/xx unknown
- 1998-04-15 SK SK1419-99A patent/SK288559B6/sk active Protection Beyond IP Right Term
- 1998-04-15 NZ NZ500253A patent/NZ500253A/xx not_active IP Right Cessation
- 1998-04-15 HU HU0001400A patent/HU230547B1/hu unknown
- 1998-04-15 AT AT98918244T patent/ATE363533T1/de active
- 1998-04-16 TW TW087105837A patent/TW589376B/zh not_active IP Right Cessation
1999
- 1999-10-15 NO NO19995044A patent/NO325175B1/no not_active IP Right Cessation
- 1999-10-21 BG BG103824A patent/BG65242B1/bg unknown
2001
- 2001-11-30 AU AU95234/01A patent/AU779461C/en not_active Expired
2005
- 2005-04-27 AU AU2005201799A patent/AU2005201799B2/en not_active Expired
2006
- 2006-01-19 US US11/336,067 patent/US7923008B2/en not_active Expired - Fee Related
2007
- 2007-09-04 JP JP2007228804A patent/JP5001758B2/ja not_active Expired - Lifetime
2008
- 2008-06-05 AU AU2008202516A patent/AU2008202516A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SK288559B6 (sk)	2018-05-02
JP2008054682A (ja)	2008-03-13
ES2284203T5 (es)	2016-03-11
SI0975754T2 (sl)	2016-04-29
AU9523401A (en)	2002-01-24
HUP0001400A2 (en)	2000-07-28
EA199900939A1 (ru)	2000-08-28
PL190092B1 (pl)	2005-10-31
NO995044L (no)	1999-12-15
AU2005201799A1 (en)	2005-05-26
DE69837845D1 (de)	2007-07-12
HK1022330A1 (en)	2000-08-04
DK0975754T4 (en)	2016-03-21
JP2001526532A (ja)	2001-12-18
AU2008202516A1 (en)	2008-06-26
US20060246064A1 (en)	2006-11-02
DK0975754T3 (da)	2007-10-01
DE69837845T3 (de)	2016-06-23
EE05496B1 (et)	2011-12-15
AU7120598A (en)	1998-11-11
EP0975754B1 (de)	2007-05-30
IL132304A0 (en)	2001-03-19
DE69837845T2 (de)	2008-01-31
RO128635A2 (ro)	2013-07-30
TW589376B (en)	2004-06-01
TR199902512T2 (xx)	2000-06-21
AU743257B2 (en)	2002-01-24
EP1717315A2 (de)	2006-11-02
CZ359899A3 (cs)	2000-02-16
EP1717315A3 (de)	2007-06-20
ID23855A (id)	2000-05-25
US7923008B2 (en)	2011-04-12
SK141999A3 (en)	2000-05-16
EE9900611A (et)	2000-08-15
HUP0001400A3 (en)	2001-12-28
ES2284203T3 (es)	2007-11-01
SI0975754T1 (sl)	2007-10-31
CA2285746A1 (en)	1998-10-22
JP5001758B2 (ja)	2012-08-15
CN1264427A (zh)	2000-08-23
BG103824A (en)	2000-05-31
NZ500253A (en)	2002-09-27
WO1998046751A1 (en)	1998-10-22
AU779461B2 (en)	2005-01-27
BG65242B1 (bg)	2007-09-28
NO995044D0 (no)	1999-10-15
BR9808545A (pt)	2000-05-23
AU2005201799B2 (en)	2008-06-12
HU230547B1 (hu)	2016-11-28
EP0975754B2 (de)	2016-01-06
EP0975754A1 (de)	2000-02-02
CA2285746C (en)	2010-09-28
NO325175B1 (no)	2008-02-11
AU779461C (en)	2005-10-13
EA003636B1 (ru)	2003-08-28
CZ302262B6 (cs)	2011-01-19
PL336311A1 (en)	2000-06-19

Legal Events

Date

Code

Title

Description

2007-11-15

UEP

Publication of translation of european patent specification

Ref document number: 0975754

Country of ref document: EP

Publication	Publication Date	Title
DE69837845D1 (de)	2007-07-12	Osteoprotegerin bindende proteine und rezeptoren
Kasugai et al.	1991	Differential regulation of the 55 and 44 kDa forms of secreted phosphoprotein 1 (SPP-1, osteopontin) in normal and transformed rat bone cells by osteotropic hormones, growth factors and a tumor promoter
Marchbank et al.	1998	Dimerization of human pS2 (TFF1) plays a key role in its protective/healing effects
ATE283916T1 (de)	2004-12-15	Menschliche metabotropische glutamatrezeptor untertype hmglur7 und verwandte dns-verbindungen
EP2325316B8 (de)	2017-04-19	Neues Hämopoietin Receptorprotein, NR10
EA199700143A1 (ru)	1997-12-30	Способ и композиция ждя липидизации гидрофильных молекул
ATE159429T1 (de)	1997-11-15	Methode zum überbringen von agenzien an zielzellen
DE69535641D1 (de)	2007-12-27	Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
BRPI9809391B8 (pt)	2021-05-25	processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
BR9814335A (pt)	2000-10-10	Proteìna, exceto as existentes ao natural, polinucleotìdeo substancialmente puro, anticorpo elaborado por um processo que compreende a etapa de injetar uma preparação farmaceuticamente aceitável, vetor para expressar o drr-1 de rato, vetor, célula hospedeira drr-1 de rato, drr-1 de ser humano, drr-2 de ser humano, drr-3 de ser humano, drr-4 de ser humano, drr-5 de ser humano, drr-6 de ser humano recombinantes, e, processo para ensaiar um composto de teste quanto à sua capacidade para ligar-se a ou para ativar um receptor especìfico de gânglios da raiz dorsal ligado à proteìna g (drr)
LU91759I2 (fr)	2011-01-24	Denosumab et ses dérivés pharmaceutique acceptables (PROLIA®)
EA200300381A1 (ru)	2003-10-30	Нуклеиновые кислоты и полипептиды нового рецептора
ATE267255T1 (de)	2004-06-15	Ob proteinderivate mit verlängerter halbwertzeit
ATE183514T1 (de)	1999-09-15	Peptide des menschlichen proteins p53 zum gebrauch in menschlichen-zytotoxischen-t-zell- antwort-induzierenden kompositionen sowie menschliche p53-protein-spezifische t-lymphocyten
DK113389A (da)	1989-09-18	Monoklonale antistoffer
BR9508467A (pt)	1997-12-23	Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal
WO2001090151A3 (en)	2002-10-17	Human receptor proteins; related reagents and methods
ATE426028T1 (de)	2009-04-15	Zellvolumenregulierte humane kinase h-sgk
BR0013043A (pt)	2002-04-30	Proteìna isolada, anticorpo isolado, composição, método de regulação de reação imunológica em animais, método de tratamento de câncer em animais, molécula de ácido nucleico isolado, molécula de ácido nucleico recombinante, célula recombinante e vìrus recombinante
DK0877803T3 (da)	2005-09-19	OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
WO1997007135A3 (en)	1997-05-22	Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof
ATE407944T1 (de)	2008-09-15	Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
WO1999019480A3 (en)	1999-06-24	Human receptor proteins; related reagents and methods
GEP20002244B (en)	2000-09-25	Osteoprotegerin